Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pharmaxis Ltd ( (AU:SNT) ) has shared an update.
Syntara Limited announced an investor webinar to discuss its quarterly update and recent developments, including the filing of its Appendix 4C Quarterly Cash Flow Report after an administrative delay. The company’s securities were temporarily suspended due to the delay, but are expected to resume trading shortly. This announcement highlights Syntara’s ongoing efforts in drug development, particularly with its lead candidate amsulostat for myelofibrosis, and its strategic focus on advancing treatments for fibrotic and inflammatory diseases. The webinar aims to engage shareholders and investors, providing insights into the company’s progress and future plans.
The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.12 price target. To see the full list of analyst forecasts on Pharmaxis Ltd stock, see the AU:SNT Stock Forecast page.
More about Pharmaxis Ltd
Syntara Limited is a clinical-stage drug development company specializing in targeting extracellular matrix dysfunction. Utilizing expertise in amine oxidase chemistry, Syntara develops novel medicines for blood cancers and conditions related to inflammation and fibrosis. Their lead candidate, amsulostat, is being developed for myelofibrosis and has received Fast Track Designation from the FDA. The company is also advancing other drug candidates for various fibrotic and inflammatory diseases, including kidney fibrosis and neurodegenerative diseases like Parkinson’s. Syntara is listed on the Australian Securities Exchange and is based in Sydney, Australia.
Average Trading Volume: 9,771,429
Technical Sentiment Signal: Sell
Current Market Cap: A$97.56M
For an in-depth examination of SNT stock, go to TipRanks’ Overview page.